References
- Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020; 38:1895–904.
- Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020; 324:1980–91.
- Taskovska M, Kreft ME, Smrkolj T. Current and innovative approaches in the treatment of non-muscle invasive bladder cancer: the role of transurethral resection of bladder tumor and organoids. Radiol Oncol. 2020; 54:135–43.
- Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2016; 388:2796–810.
- Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette–Guerin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013; 63:462–72.
- Deininger S, Törzsök P, Mitterberger M, Pallauf M, Oswald D, Deininger C, Lusuardi L. From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in Bacillus Calmette-Guérin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC). Cancers (Basel). 2022; 14:694.
- Califano G, Ouzaid I, Verze P, Stivalet N, Hermieu J F, Xylinas E. New immunotherapy treatments in non-muscle invasive bladder cancer. Arch Esp Urol. 2020; 73:945–53.
- Grossmann NC, Rajwa P, Quhal F, Konig F, Mostafaei H, Laukhtina E, et al. Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study. Eur Urol Open Sci. 2022; 39:14–21.
- Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020; 70:404–23.
- Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, et al. Application of nanotechnology in the diagnosis and treatment of bladder cancer. J Nanobiotechnology. 2021; 19:393.
- Lin PC, Ji LL, Zhong XJ, Li JJ, Wang X, Shang XY, et al. Taraxastane-type triterpenoids from the medicinal and edible plant Cirsium setosum. Chin J Nat Med. 2019; 17:22–6.
- Saikia S, Bordoloi M. Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets. 2019; 20:501–21.
- Aucar MG, Cavasotto CN. Molecular docking using quantum mechanical-based methods. Methods Mol Biol. 2020; 2114:269–84.
- Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014; 6:13.
- Rey-Cárdenas M, Guerrero-Ramos F, Gómez de Liano Lista A, Carretero-González A, Bote H, Herrera-Juárez M, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future. Cancer Treat Rev. 2021; 93:102142.
- Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci. 2019; 20:3177.
- Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment. J Ovarian Res. 2019; 12:55.
- Davoodvandi A, Shabani Varkani M, Clark CCT, Jafarnejad S. Quercetin as an anticancer agent: focus on esophageal cancer. J Food Biochem. 2020; 44:e13374.
- Kasiri N, Rahmati M, Ahmadi L, Eskandari N, Motedayyen H. Therapeutic potential of quercetin on human breast cancer in different dimensions. Inflammopharmacology. 2020; 28:39–62.
- Tan DQ, Liu X H. [Mechanism in growth inhibition of quercetin on human bladder cancer cell line]. Zhongguo Zhong Yao Za Zhi. 2017; 42:1742–6.
- Yun S, Lee YJ, Choi J, Kim ND, Han DC, Kwon BM. Acacetin inhibits the growth of STAT3-activated DU145 prostate cancer cells by directly binding to signal transducer and activator of transcription 3 (STAT3). Molecules. 2021; 26:6204.
- Aslan BT, Ertugrul B, Iplik ES, Cakmakoglu B. Apoptotic effects of acacetin in human colon cancer HT-29 and HCT 116 cells. J Cancer Res Ther. 2021; 17:1479–82.
- Liao H, Zhu D, Bai M, Chen H, Yan S, Yu J, et al. Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway. Cancer Cell Int. 2020; 20:480.
- Zhao H, Zhang X, Wang M, Lin Y, Zhou S. Stigmasterol simultaneously induces apoptosis and protective autophagy by inhibiting Akt/mTOR pathway in gastric cancer cells. Front Oncol. 2021; 11:629008.
- Li K, Yuan D, Yan R, Meng L, Zhang Y, Zhu K. Stigmasterol exhibits potent antitumor effects in human gastric cancer cells mediated via inhibition of cell migration, cell cycle arrest, mitochondrial mediated apoptosis and inhibition of JAK/STAT signalling pathway. J BUON. 2018; 23:1420–5.
- Bae H, Park S, Ham J, Song J, Hong T, Choi JH, et al. ER-mitochondria calcium flux by beta-sitosterol promotes cell death in ovarian cancer. Antioxidants (Basel). 2021; 10:1583.
- Shathviha PC, Ezhilarasan D, Rajeshkumar S, Selvaraj J. Beta-sitosterol mediated silver nanoparticles induce cytotoxicity in human colon cancer HT-29 cells. Avicenna J Med Biotechnol. 2021; 13:42–6.
- Cao ZQ, Wang XX, Lu L, Xu JW, Li XB, Zhang GR, et al. Corrigendum: beta-sitosterol and gemcitabine exhibit synergistic anti-pancreatic cancer activity by modulating apoptosis and inhibiting epithelial-mesenchymal transition by deactivating Akt/GSK-3beta signaling. Front Pharmacol. 2020; 11:565535.
- Fettke H, Kwan EM, Bukczynska P, Steen JA, Docanto M, Ng N, et al. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer. Prostate. 2021; 81:992–1001.
- Cai M, Liang X, Sun X, Chen H, Dong Y, Wu L, et al. Nuclear receptor coactivator 2 promotes human breast cancer cell growth by positively regulating the MAPK/ERK pathway. Front Oncol. 2019; 9:164.
- Lin Z, Yang F, Lu D, Sun W, Zhu G, Lan B. Knockdown of NCOA2 inhibits the growth and progression of gastric cancer by affecting the Wnt signaling pathway-related protein expression. Technol Cancer Res Treat. 2020; 19:1533033820928072.
- Kao YC, Bennett JA, Suurmeijer AJH, Dickson BC, Swanson D, Wanjari P, et al. Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Mod Pathol. 2021; 34:1203–12.
- Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, et al. ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood. 2022; 139:399–412.
- Tanaka R, Inoue K, Yamada Y, Yoshida M, Shima H, Ito J, et al. A case of primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion and systematic meta-review. J Neurooncol. 2021; 154:247–56.
- Brunetti M, Panagopoulos I, Gorunova L, Davidson B, Heim S, Micci F. RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). Genes Chromosomes Cancer. 2018; 57:176–81.
- Bostrom PJ, Uotila P, Rajala P, Nurmi M, Huhtaniemi I, Laato M. Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res. 2001; 29:20–4.
- Farivar-Mohseni H, Kandzari SJ, Zaslau S, Riggs DR, Jackson BJ, McFadden DW. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Am J Surg. 2004; 188:505–10.
- Španko M, Strnadová K, Pavlíček AJ, Szabo P, Kodet O, Valach J, et al. IL-6 in the ecosystem of head and neck cancer: possible therapeutic perspectives. Int J Mol Sci. 2021; 22:11027.
- Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim Biophys Acta Rev Cancer. 2021; 1876:188639.
- Abaurrea A, Araujo AM, Caffarel MM. The role of the IL-6 cytokine family in epithelial-mesenchymal plasticity in cancer progression. Int J Mol Sci. 2021; 22:8334.
- Chen MF, Lin PY, Wu CF, Chen WC, Wu CT. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One. 2013; 8:e61901.
- Zheng Z, Zheng X, Zhu Y, Yao Z, Zhao W, Zhu Y, et al. IL-6 promotes the proliferation and immunosuppressive function of myeloid-derived suppressor cells via the MAPK signaling pathway in bladder cancer. Biomed Res Int. 2021; 2021:5535578.
- Tong S, Hu X, Li Y. Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer. Urol Oncol. 2022; 40:412.e1–412.e8.
- Mao X, Zhang N, Xiao J, Wu H, Ding K. Hypoxia-induced autophagy enhances cisplatin resistance in human bladder cancer cells by targeting hypoxia-inducible factor-1alpha. J Immunol Res. 2021; 2021:8887437.
- Gao Y, Liu S, Guo Q, Zhang S, Zhao Y, Wang H, et al. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway. Int J Biol Sci. 2019; 15:1488–99.
- Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021; 94:102154.
- Zhu Y, Piao C, Zhang Z, Jiang Y, Kong C. The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics. Genomics. 2022; 114:125–37.
- Zhou Z, Xu S, Jiang L, Tan Z, Wang J. A systematic pan-cancer analysis of CASP3 as a potential target for immunotherapy. Front Mol Biosci. 2022; 9:776808.
- Gao D, Niu Q, Gong Y, Guo Q, Zhang S, Wang Y, et al. Y-box binding protein 1 regulates angiogenesis in bladder cancer via miR-29b-3p-VEGFA pathway. J Oncol. 2021; 2021:9913015.
- Tate T, Xiang T, Wobker SE, Zhou M, Chen X, Kim H, et al. Pparg signaling controls bladder cancer subtype and immune exclusion. Nat Commun. 2021; 12:6160.
- Chen Y, Huang Y, Gao X, Li Y, Lin J, Chen L, et al. CCND1 amplification contributes to immunosuppression and is associated with a poor prognosis to immune checkpoint inhibitors in solid tumors. Front Immunol. 2020; 11:1620.
- Chen Z, Chen X, Xie R, Huang M, Dong W, Han J, et al. DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 2019; 27:326–41.
- Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate AKT-regulated survival in prostate cancer cells. Cancer Res. 2002; 62:2227–31.
- Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008; 9:628–38.
- Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y, et al. Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018; 17:120.
- Jain R K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014; 26:605–22.
- Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871–90.
- Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017; 168:629–43.
- Sengupta S, George RE. Super-enhancer-driven transcriptional dependencies in cancer. Trends Cancer. 2017; 3:269–81.
- Schier AC, Taatjes DJ. Structure and mechanism of the RNA polymerase II transcription machinery. Genes Dev. 2020; 34:465–88.
- Martin RD, Hebert TE, Tanny JC. Therapeutic targeting of the general RNA polymerase II transcription machinery. Int J Mol Sci. 2020; 21:3354.
- Hryniewicz-Jankowska A, Augoff K, Sikorski AF. The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp Biol Med (Maywood). 2019; 244:1053–61.
- Liu W, Xu J, Zhang C. Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers: a meta-analysis. Medicine (Baltimore). 2018; 97:e11522
- Bonczek O, Wang L, Gnanasundram SV, Chen S, Haronikova L, Zavadil-Kokas F, et al. DNA and RNA binding proteins: from motifs to roles in cancer. Int J Mol Sci. 2022; 23:9329.
- Ji X, Li J, Zhu L, Cai J, Zhang J, Qu Y, et al. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. J Surg Res. 2013; 185:84–91.
- Mu QJ, Li HL, Yao Y, Liu SC, Yin CG, Ma XZ. Chromodomain helicase/ATPase DNA-binding protein 1-like gene (CHD1L) expression and implications for invasion and metastasis of breast cancer. PLoS One. 2015; 10:e0143030.
- Qi J, Ronai ZA. Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat. 2015; 23:1–11.
- Duan S, Pagano M. Ubiquitin ligases in cancer: functions and clinical potentials. Cell Chem Biol. 2021; 28:918–33.
- Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013; 13:83–96.
- Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020; 21:607–32.
- Kuchay S, Duan S, Schenkein E, Peschiaroli A, Saraf A, Florens L, et al. FBXL2-and PTPL1-mediated degradation of p110-free p85beta regulatory subunit controls the PI(3)K signalling cascade. Nat Cell Biol. 2013; 15:472–80.
- Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021; 21:703. doi: 10.1186/s12935-021-02396-8
- Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020; 12:674–87.
- Ziaran S, Harsanyi S, Bevizova K, Varchulova Novakova Z, Trebaticky B, Bujdak P, et al. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem. 2020; 64:3098. doi: 10.4081/ejh.2020.3098
- Zhu C, Zhu Q, Wang C, Zhang L, Wei F, Cai Q. Hostile takeover: manipulation of HIF-1 signaling in pathogen-associated cancers (Review). Int J Oncol. 2016; 49:1269–76.
- Wang JZ, Zhu W, Han J, Yang X, Zhou R, Lu HC, et al. The role of the HIF-1alpha/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021; 41:560–75.
- Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF Targeting. Int J Mol Sci. 2018; 19:1442. doi: 10.3390/ijms19051442
- Marsh HP, Haldar NA, Bunce M, Marshall SE, le Monier K, Winsey SL, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer. 2003; 89:1096–101.
- Kachrilas S, Dellis A, Papatsoris A, Avgeris S, Anastasiou D, Gavriil A, et al. PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer. J BUON. 2019; 24:329–37.
- Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022; 41:175.